<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">nnp</journal-id><journal-title-group><journal-title xml:lang="en">Neurology, Neuropsychiatry, Psychosomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>Неврология, нейропсихиатрия, психосоматика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2711</issn><issn pub-type="epub">2310-1342</issn><publisher><publisher-name>"IMA-Press", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/2074-2711-2021-3-93-98</article-id><article-id custom-type="elpub" pub-id-type="custom">nnp-1583</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group></article-categories><title-group><article-title>Post-covid syndrome: a review of pathophysiology, neuropsychiatric manifestations and treatment perspectives</article-title><trans-title-group xml:lang="ru"><trans-title>Постковидный синдром: обзор знаний о патогенезе, нейропсихиатрических проявлениях и перспективах лечения</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хасанова</surname><given-names>Д. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Khasanova</surname><given-names>D. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>420012, Казань, ул. Бутлерова, 49,</p><p>420101, Казань, ул. Карбышева, 12а </p></bio><bio xml:lang="en"><p>49, Butlerov St., Kazan 420012, </p><p>12a, Karbyshev St., Kazan 420101</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Житкова</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zhitkova</surname><given-names>Yu. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Юлия Владимировна Житкова</p><p>420101, Казань, ул. Карбышева, 12а </p></bio><bio xml:lang="en"><p>Yulia Vladimirovna Zhitkova</p><p>12a, Karbyshev St., Kazan 420101</p></bio><email xlink:type="simple">zhitkova@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Васкаева</surname><given-names>Г. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Vaskaeva</surname><given-names>G. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>420012, Казань, ул. Бутлерова, 49</p></bio><bio xml:lang="en"><p>49, Butlerov St., Kazan 420012</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Казанский государственный медицинский университет» Минздрава России;&#13;
ГАУЗ «Межрегиональный клинико-диагностический центр»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kazan State Medical University, Ministry of Health of Russia; &#13;
Interregional Clinical Diagnostic Center, Ministry of Healthof the Republic of Tatarstan</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГАУЗ «Межрегиональный клинико-диагностический центр»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Interregional Clinical Diagnostic Center, Ministry of Healthof the Republic of Tatarstan</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБОУ ВО «Казанский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kazan State Medical University, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>23</day><month>06</month><year>2021</year></pub-date><volume>13</volume><issue>3</issue><fpage>93</fpage><lpage>98</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Khasanova D.R., Zhitkova Y.V., Vaskaeva G.R., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Хасанова Д.Р., Житкова Ю.В., Васкаева Г.Р.</copyright-holder><copyright-holder xml:lang="en">Khasanova D.R., Zhitkova Y.V., Vaskaeva G.R.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://nnp.ima-press.net/nnp/article/view/1583">https://nnp.ima-press.net/nnp/article/view/1583</self-uri><abstract><p>In the context of the COVID-19 pandemic, healthcare is faced with several new problems, one of which is a post-covid syndrome. Symptoms in many COVID-19 survivors can persist for a long time, significantly affecting the quality of life and work performance. All of the above makes post-covid syndrome a socially significant disease, requires dynamic follow-up of such patients, and rehabilitation programs development. We are currently at the stage of accumulating knowledge about the SARS-CoV-2 pathophysiology and morphogenesis and its long-term consequences. This article discusses neuropsychiatric aspects of the post-covid syndrome: pathogenetic hypotheses, clinical features, and potentially promising treatment strategies.</p></abstract><trans-abstract xml:lang="ru"><p>В условиях пандемии COVID-19 медицина столкнулась с рядом новых проблем, одной из которых является постковидный синдром. У многих людей, перенесших COVID-19, симптомы могут сохраняться длительное время, значительно влияя на качество жизни и работоспособность. Это делает постковидный синдром социально значимым заболеванием, требует динамического наблюдения за больными и разработки реабилитационных программ. В настоящее время мы находимся на этапе накопления знаний о патоморфогенезе SARS-CoV-2 и его долгосрочных последствиях. Обсуждаются нейропсихиатрические аспекты постковидного синдрома: патогенетические гипотезы, клинические особенности и потенциально перспективные лечебные стратегии.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>COVID-19</kwd><kwd>постковидный синдром</kwd><kwd>нейропсихиатрические проявления</kwd><kwd>патогенез</kwd><kwd>лечебные стратегии</kwd></kwd-group><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>post-covid syndrome</kwd><kwd>neuropsychiatric manifestations</kwd><kwd>pathophysiology</kwd><kwd>treatment strategies</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Статья спонсируется компанией Ever Neuro Pharma</funding-statement><funding-statement xml:lang="en">This article has been supported by Ever Neuro Pharma</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Carfi A, Bernabei R, Landi F, et al. Persistent Symptoms in Patients after Acute COVID-19. JAMA. 2020 Aug 11;324(6):603-5. doi: 10.1001/jama.2020.12603</mixed-citation><mixed-citation xml:lang="en">Carfi A, Bernabei R, Landi F, et al. Persistent Symptoms in Patients after Acute COVID-19. JAMA. 2020 Aug 11;324(6):603-5. doi: 10.1001/jama.2020.12603</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network – United States, March–June 2020. MMWR Morb Mortal Wkly Rep. 2020 Jul 31;69(30):993-8. doi: 10.15585/mmwr.mm6930e1</mixed-citation><mixed-citation xml:lang="en">Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network – United States, March–June 2020. MMWR Morb Mortal Wkly Rep. 2020 Jul 31;69(30):993-8. doi: 10.15585/mmwr.mm6930e1</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Van den Borst B, Peters JB, Brink M, et al. Comprehensive health assessment three months after recovery from acute COVID-19. Clin Infect Dis. 2020 Nov 21;ciaa1750. doi: 10.1093/cid/ciaa1750. Online ahead of print.</mixed-citation><mixed-citation xml:lang="en">Van den Borst B, Peters JB, Brink M, et al. Comprehensive health assessment three months after recovery from acute COVID-19. Clin Infect Dis. 2020 Nov 21;ciaa1750. doi: 10.1093/cid/ciaa1750. Online ahead of print.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Kumari P, Rothan HA, Natekar JP, et al. Neuroinvasion and Encephalitis Following Intranasal Inoculation of SARS-CoV-2 in K18- hACE2 Mice. Viruses. 2021 Jan 19;13(1):132. doi: 10.3390/v13010132</mixed-citation><mixed-citation xml:lang="en">Kumari P, Rothan HA, Natekar JP, et al. Neuroinvasion and Encephalitis Following Intranasal Inoculation of SARS-CoV-2 in K18- hACE2 Mice. Viruses. 2021 Jan 19;13(1):132. doi: 10.3390/v13010132</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Алексеева НТ, Соколов ДА, Никитюк ДБ и др. Молекулярные и клеточные механизмы повреждения центральной нервной системы при COVID-19. Журнал анатомии и гистопатологии. 2020;9(3):72-85.</mixed-citation><mixed-citation xml:lang="en">Alekseyeva NT, Sokolov DA, Nikityuk DB, et al. Molecular and cellular mechanisms of damage to the central nervous system in COVID-19. Zhurnal anatomii i gistopatologii. 2020;9(3):72-85 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Futtrup J, Margolinsky R, Benros ME, et al. Blood-brain barrier pathology in patients with severe mental disorders: a systematic review and meta-analysis of biomarkers in casecontrol studies. Brain Behav Immun Health. 2020 Nov;90:364-80. doi: 10.1016/j.bbi.2020.08.028. Epub 2020 Sep 3.</mixed-citation><mixed-citation xml:lang="en">Futtrup J, Margolinsky R, Benros ME, et al. Blood-brain barrier pathology in patients with severe mental disorders: a systematic review and meta-analysis of biomarkers in casecontrol studies. Brain Behav Immun Health. 2020 Nov;90:364-80. doi: 10.1016/j.bbi.2020.08.028. Epub 2020 Sep 3.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Z, Yang Y, Liang X. COVID-19 Associated Ischemic Stroke and Hemorrhagic Stroke: Incidence, Potential Pathological Mechanism, and Management. Front Neurol. 2020 Oct 27;11:571996. doi: 10.3389/fneur.2020.571996. eCollection 2020.</mixed-citation><mixed-citation xml:lang="en">Wang Z, Yang Y, Liang X. COVID-19 Associated Ischemic Stroke and Hemorrhagic Stroke: Incidence, Potential Pathological Mechanism, and Management. Front Neurol. 2020 Oct 27;11:571996. doi: 10.3389/fneur.2020.571996. eCollection 2020.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Lu Y, Li X, Geng D, et al. Cerebral MicroStructural Changes in COVID-19 Patients An MRI-based 3-month Follow-up Study. EClinicalMedicine. 2020 Aug;25:100484. doi: 10.1016/j.eclinm.2020.100484. Epub 2020 Aug 3.</mixed-citation><mixed-citation xml:lang="en">Lu Y, Li X, Geng D, et al. Cerebral MicroStructural Changes in COVID-19 Patients An MRI-based 3-month Follow-up Study. EClinicalMedicine. 2020 Aug;25:100484. doi: 10.1016/j.eclinm.2020.100484. Epub 2020 Aug 3.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Miners S, Kehoe PG, Love S. Cognitive impact of COVID-19: looking beyond the short term. Alzheimer's Res Ther. 2020 Dec 30;12(1):170. doi: 10.1186/s13195-020-00744-w</mixed-citation><mixed-citation xml:lang="en">Miners S, Kehoe PG, Love S. Cognitive impact of COVID-19: looking beyond the short term. Alzheimer's Res Ther. 2020 Dec 30;12(1):170. doi: 10.1186/s13195-020-00744-w</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Carvalho-Schneider C, Laurent E, Lemaignen A, et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect. 2021 Feb;27(2):258-63. doi: 10.1016/j.cmi.2020.09.052. Epub 2020 Oct 5.</mixed-citation><mixed-citation xml:lang="en">Carvalho-Schneider C, Laurent E, Lemaignen A, et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect. 2021 Feb;27(2):258-63. doi: 10.1016/j.cmi.2020.09.052. Epub 2020 Oct 5.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Garrigues E, Janvier P, Kherabi Y, et al. Post-discharge persistent symptoms and healthrelated quality of life after hospitalization for COVID-19. J Infect. 2020 Dec;81(6):e4-e6. doi: 10.1016/j.jinf.2020.08.029. Epub 2020 Aug 25.</mixed-citation><mixed-citation xml:lang="en">Garrigues E, Janvier P, Kherabi Y, et al. Post-discharge persistent symptoms and healthrelated quality of life after hospitalization for COVID-19. J Infect. 2020 Dec;81(6):e4-e6. doi: 10.1016/j.jinf.2020.08.029. Epub 2020 Aug 25.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Beaud V, Crottaz-Herbette S, Dunet V, et al. Pattern of cognitive deficits in severe COVID-19. J Neurol Neurosurg Psychiatry. 2021 May;92(5):567-8. doi: 10.1136/jnnp-2020-325173. Epub 2020 Nov 20.</mixed-citation><mixed-citation xml:lang="en">Beaud V, Crottaz-Herbette S, Dunet V, et al. Pattern of cognitive deficits in severe COVID-19. J Neurol Neurosurg Psychiatry. 2021 May;92(5):567-8. doi: 10.1136/jnnp-2020-325173. Epub 2020 Nov 20.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020 Jul;7(7):611-27. doi: 10.1016/S2215-0366(20)30203-0. Epub 2020 May 18.</mixed-citation><mixed-citation xml:lang="en">Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020 Jul;7(7):611-27. doi: 10.1016/S2215-0366(20)30203-0. Epub 2020 May 18.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Almeria M, Cejudo JC, Sotoca J, et al. Cognitive profile following COVID-19 infection: Clinical predictors leading to neuropsychological impairment. Brain, Behav Immun Health. 2020 Dec;9:100163. doi: 10.1016/j.bbih.2020.100163. Epub 2020 Oct 22.</mixed-citation><mixed-citation xml:lang="en">Almeria M, Cejudo JC, Sotoca J, et al. Cognitive profile following COVID-19 infection: Clinical predictors leading to neuropsychological impairment. Brain, Behav Immun Health. 2020 Dec;9:100163. doi: 10.1016/j.bbih.2020.100163. Epub 2020 Oct 22.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Naughton SX, Raval U, Pasinetti GM. Potential Novel Role of COVID-19 in Alzheimer’s disease and preventative mitigation strategies. J Alzheimers Dis. 2020;76(1):21- 5. doi: 10.3233/JAD-200537</mixed-citation><mixed-citation xml:lang="en">Naughton SX, Raval U, Pasinetti GM. Potential Novel Role of COVID-19 in Alzheimer’s disease and preventative mitigation strategies. J Alzheimers Dis. 2020;76(1):21- 5. doi: 10.3233/JAD-200537</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Pinna P, Grewal P, Hall JP, et al. Neurological manifestations and COVID-19: experiences from a tertiary care center at the frontline. J Neurol Sci. 2020 Aug 15;415:116969. doi: 10.1016/j.jns.2020.116969. Epub 2020 Jun 3.</mixed-citation><mixed-citation xml:lang="en">Pinna P, Grewal P, Hall JP, et al. Neurological manifestations and COVID-19: experiences from a tertiary care center at the frontline. J Neurol Sci. 2020 Aug 15;415:116969. doi: 10.1016/j.jns.2020.116969. Epub 2020 Jun 3.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Magoon R. Pulmonary vasculature in COVID-19: mechanism to monitoring! Korean J Anesthesiol. 2021 Apr;74(2):186-7. doi: 10.4097/kja.20536. Epub 2020 Oct 5.</mixed-citation><mixed-citation xml:lang="en">Magoon R. Pulmonary vasculature in COVID-19: mechanism to monitoring! Korean J Anesthesiol. 2021 Apr;74(2):186-7. doi: 10.4097/kja.20536. Epub 2020 Oct 5.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Love S, Chalmers K, Ince P, et al. Development, appraisal, validation and implementation of a consensus protocol for the assessment of cerebral amyloid angiopathy in post-mortem brain tissue. Am J Neurodegener Dis. 2014 Mar 28;3(1):19-32. eCollection 2014.</mixed-citation><mixed-citation xml:lang="en">Love S, Chalmers K, Ince P, et al. Development, appraisal, validation and implementation of a consensus protocol for the assessment of cerebral amyloid angiopathy in post-mortem brain tissue. Am J Neurodegener Dis. 2014 Mar 28;3(1):19-32. eCollection 2014.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Kehoe PG, Wong S, Mulhim NAL, et al. Angiotensin-converting enzyme 2 is reduced in Alzheimer’s disease in association with increasing amyloid-beta and tau pathology. Alzheimers Res Ther. 2016 Nov 25;8(1):50. doi: 10.1186/s13195-016-0217-7</mixed-citation><mixed-citation xml:lang="en">Kehoe PG, Wong S, Mulhim NAL, et al. Angiotensin-converting enzyme 2 is reduced in Alzheimer’s disease in association with increasing amyloid-beta and tau pathology. Alzheimers Res Ther. 2016 Nov 25;8(1):50. doi: 10.1186/s13195-016-0217-7</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Kuo CL, Pilling LC, Atkins JL, et al. APOE e4 Genotype Predicts Severe COVID-19 in the UK Biobank Community Cohort. J Gerontol A Biol Sci Med Sci. 2020 Oct 15;75(11):2231-2. doi: 10.1093/gerona/glaa131</mixed-citation><mixed-citation xml:lang="en">Kuo CL, Pilling LC, Atkins JL, et al. APOE e4 Genotype Predicts Severe COVID-19 in the UK Biobank Community Cohort. J Gerontol A Biol Sci Med Sci. 2020 Oct 15;75(11):2231-2. doi: 10.1093/gerona/glaa131</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Taquet M, Luciano S, Geddes JR, et al. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 2021 Feb;8(2):130-40. doi: 10.1016/S2215-0366(20)30462-4. Epub 2020 Nov 9.</mixed-citation><mixed-citation xml:lang="en">Taquet M, Luciano S, Geddes JR, et al. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 2021 Feb;8(2):130-40. doi: 10.1016/S2215-0366(20)30462-4. Epub 2020 Nov 9.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Woo MS, Malsy J, Pöttgen J, et al. Frequent neurocognitive deficits after recovery from mild COVID-19. Brain Commun. 2020 Nov 23;2(2):fcaa205. doi: 10.1093/braincomms/fcaa205. eCollection 2020.</mixed-citation><mixed-citation xml:lang="en">Woo MS, Malsy J, Pöttgen J, et al. Frequent neurocognitive deficits after recovery from mild COVID-19. Brain Commun. 2020 Nov 23;2(2):fcaa205. doi: 10.1093/braincomms/fcaa205. eCollection 2020.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Lee Y, Subramaniapillai M, Brietzke E, et al. Anti-cytokine agents for anhedonia: targeting inflammation and the immune system to treat dimensional disturbances in depression. Ther Adv Psychopharmacol. 2018 Nov 19;8(12):337-48. doi: 10.1177/2045125318791944. eCollection 2018 Dec.</mixed-citation><mixed-citation xml:lang="en">Lee Y, Subramaniapillai M, Brietzke E, et al. Anti-cytokine agents for anhedonia: targeting inflammation and the immune system to treat dimensional disturbances in depression. Ther Adv Psychopharmacol. 2018 Nov 19;8(12):337-48. doi: 10.1177/2045125318791944. eCollection 2018 Dec.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Alpert O, Begun L, Garren P, et al., Cytokine storm induced new onset depression in patients with COVID-19. A new look into the association between depression and cytokines – two case reports. Brain Behav Immun Health. 2020 Dec;9:100173. doi: 10.1016/j.bbih.2020.100173. Epub 2020 Nov 3.</mixed-citation><mixed-citation xml:lang="en">Alpert O, Begun L, Garren P, et al., Cytokine storm induced new onset depression in patients with COVID-19. A new look into the association between depression and cytokines – two case reports. Brain Behav Immun Health. 2020 Dec;9:100173. doi: 10.1016/j.bbih.2020.100173. Epub 2020 Nov 3.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">De Erausquin GA, Snyder H, Carrillo M, et al. The chronic neuropsychiatric sequelae of COVID-19: The need for a prospective study of viral impact on brain functioning. Alzheimer’s Dement. 2021 Jan 5. doi: 10.1002/alz.12255. Online ahead of print.</mixed-citation><mixed-citation xml:lang="en">De Erausquin GA, Snyder H, Carrillo M, et al. The chronic neuropsychiatric sequelae of COVID-19: The need for a prospective study of viral impact on brain functioning. Alzheimer’s Dement. 2021 Jan 5. doi: 10.1002/alz.12255. Online ahead of print.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Shi J, Gao Y, Zhao L, et al. Prevalence of delirium, depression, anxiety, and post-traumatic stress disorder among COVID-19 patients: protocol for a living systematic review. Syst Rev. 2020 Nov 6;9(1):258. doi: 10.1186/s13643-020-01507-2</mixed-citation><mixed-citation xml:lang="en">Shi J, Gao Y, Zhao L, et al. Prevalence of delirium, depression, anxiety, and post-traumatic stress disorder among COVID-19 patients: protocol for a living systematic review. Syst Rev. 2020 Nov 6;9(1):258. doi: 10.1186/s13643-020-01507-2</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Barker-Davies RM, O’Sullivan O, Senaratneet KPP, et al. The Stanford Hall consensus statement for post-COVID-19 rehabilitation. Br J Sports Med. 2020 Aug;54(16):949- 59. doi: 10.1136/bjsports-2020-102596. Epub 2020 May 31.</mixed-citation><mixed-citation xml:lang="en">Barker-Davies RM, O’Sullivan O, Senaratneet KPP, et al. The Stanford Hall consensus statement for post-COVID-19 rehabilitation. Br J Sports Med. 2020 Aug;54(16):949- 59. doi: 10.1136/bjsports-2020-102596. Epub 2020 May 31.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Demeco A, Marotta N, Barletta M, et al. Rehabilitation of patients post-COVID-19 infection: a literature review. J Intern Med Res. 2020 Aug;48(8):300060520948382. doi: 10.1177/0300060520948382</mixed-citation><mixed-citation xml:lang="en">Demeco A, Marotta N, Barletta M, et al. Rehabilitation of patients post-COVID-19 infection: a literature review. J Intern Med Res. 2020 Aug;48(8):300060520948382. doi: 10.1177/0300060520948382</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Deigner HP, Haberkorn U, Kinscherf R. Apoptosis modulators in the therapy of neurodegenerative diseases. Expert Opin Investig Drugs. 2000 Apr;9(4):747-64. doi: 10.1517/13543784.9.4.747</mixed-citation><mixed-citation xml:lang="en">Deigner HP, Haberkorn U, Kinscherf R. Apoptosis modulators in the therapy of neurodegenerative diseases. Expert Opin Investig Drugs. 2000 Apr;9(4):747-64. doi: 10.1517/13543784.9.4.747</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Alvarez XA, Lombardi VR, Fernandez-Novoa L, et al. Cerebrolysin reduces microglial activation in vivo and in vitro: a potential mechanism of neuroprotection. J Neural Transm Suppl. 2000;59:281-92. doi: 10.1007/978-3-7091-6781-6-30</mixed-citation><mixed-citation xml:lang="en">Alvarez XA, Lombardi VR, Fernandez-Novoa L, et al. Cerebrolysin reduces microglial activation in vivo and in vitro: a potential mechanism of neuroprotection. J Neural Transm Suppl. 2000;59:281-92. doi: 10.1007/978-3-7091-6781-6-30</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Domzal T, Zaleska B. Cerebrolysin in treatment of acute ischemic stroke. Neurol Neurochir Pol. May-Jun 1995;29(3):325-31.</mixed-citation><mixed-citation xml:lang="en">Domzal T, Zaleska B. Cerebrolysin in treatment of acute ischemic stroke. Neurol Neurochir Pol. May-Jun 1995;29(3):325-31.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Schwab M, Antonow-Schlorke I, Zwiener U, et al. Brain-derived peptides reduce the size of cerebral infarction and loss of MAP2 immunoreactivity after focal ischemia in rats. J Neural Transm Suppl. 1998;53:299-311. doi: 10.1007/978-3-7091-6467-9-26</mixed-citation><mixed-citation xml:lang="en">Schwab M, Antonow-Schlorke I, Zwiener U, et al. Brain-derived peptides reduce the size of cerebral infarction and loss of MAP2 immunoreactivity after focal ischemia in rats. J Neural Transm Suppl. 1998;53:299-311. doi: 10.1007/978-3-7091-6467-9-26</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Бабенкова ИВ, Теселкин ОЮ, Макашова НВ, Гусева МР. Антиоксидантная активность гистохрома и некоторых лекарственных препаратов, применяемых в офтальмологии. Вестник офтальмологии. 1999;115(4):22-4.</mixed-citation><mixed-citation xml:lang="en">Babenkova IV, Teselkin OYu, Makashova NV, Guseva MR. Antioxidative activity of histochrome and some other drugs used in ophthalmology. Vestnik oftalmologii. 1999;115:22-4 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Cruz R, Francis L, Diaz-Suarez CM, et al. Short-term effects of septohippocampal pathway transsection and cerebrolysin effects on glutathione-related enzymes in the rat brain. Rev Neurol. 1998 Apr;26(152):551-4.</mixed-citation><mixed-citation xml:lang="en">Cruz R, Francis L, Diaz-Suarez CM, et al. Short-term effects of septohippocampal pathway transsection and cerebrolysin effects on glutathione-related enzymes in the rat brain. Rev Neurol. 1998 Apr;26(152):551-4.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Tatebayashi Y, Lee MH, Li L, et al. The dentate gyrus neurogenesis: a therapeutic target for Alzheimefs disease. Acta Neuropathol. 2003 Mar;105(3):225-32. doi: 10.1007/s00401-002-0636-3. Epub 2002 Nov 19.</mixed-citation><mixed-citation xml:lang="en">Tatebayashi Y, Lee MH, Li L, et al. The dentate gyrus neurogenesis: a therapeutic target for Alzheimefs disease. Acta Neuropathol. 2003 Mar;105(3):225-32. doi: 10.1007/s00401-002-0636-3. Epub 2002 Nov 19.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Chang WH, Park CH, Kim DY, et al. Cerebrolysin combined with rehabilitation promotes motor recovery in patients with severe motor impairment after stroke. BMC Neurol. 2016 Mar 2;16:31. doi: 10.1186/s12883-016-0553-z</mixed-citation><mixed-citation xml:lang="en">Chang WH, Park CH, Kim DY, et al. Cerebrolysin combined with rehabilitation promotes motor recovery in patients with severe motor impairment after stroke. BMC Neurol. 2016 Mar 2;16:31. doi: 10.1186/s12883-016-0553-z</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Montagne A, Nation DA, Sagare AP, et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature. 2020 May;581(7806):71-6. doi: 10.1038/s41586-020-2247-3. Epub 2020 Apr 29.</mixed-citation><mixed-citation xml:lang="en">Montagne A, Nation DA, Sagare AP, et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature. 2020 May;581(7806):71-6. doi: 10.1038/s41586-020-2247-3. Epub 2020 Apr 29.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Muresanu DF, Heiss W-D, Hoemberg V, et al. Cerebrolysin and Recovery After Stroke (CARS). A randomized, placebo-controlled, double-blind, multicenter trial. Stroke. 2016 Jan;47(1):151-9. doi: 10.1161/STROKEAHA.115.009416. Epub 2015 Nov 12.</mixed-citation><mixed-citation xml:lang="en">Muresanu DF, Heiss W-D, Hoemberg V, et al. Cerebrolysin and Recovery After Stroke (CARS). A randomized, placebo-controlled, double-blind, multicenter trial. Stroke. 2016 Jan;47(1):151-9. doi: 10.1161/STROKEAHA.115.009416. Epub 2015 Nov 12.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Guekht A, Moessler H, Novak PH, Gusev EI; Cerebrolysin Investigators. Cerebrolysin in vascular dementia: Improvement of clinical outcome in a randomized, double blind, placebo-controlled multicenter trial. J Stroke Cerebrovasc Dis. Jul-Aug 2011;20(4):310-8. doi: 10.1016/j.jstrokecerebrovasdis.2010.01.012. Epub 2010 Jul 24.</mixed-citation><mixed-citation xml:lang="en">Guekht A, Moessler H, Novak PH, Gusev EI; Cerebrolysin Investigators. Cerebrolysin in vascular dementia: Improvement of clinical outcome in a randomized, double blind, placebo-controlled multicenter trial. J Stroke Cerebrovasc Dis. Jul-Aug 2011;20(4):310-8. doi: 10.1016/j.jstrokecerebrovasdis.2010.01.012. Epub 2010 Jul 24.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
